| Demographics |
| Age (yr) |
70 (65–76) |
70 (64–74) |
71 (65–76) |
0.64 |
| Male |
63 (64%) |
35 (56%) |
28 (78%) |
0.03 |
| Medical history |
| Ischemic heart failure |
51 (52%) |
29 (46%) |
22 (61%) |
0.21 |
| Hypertension |
32 (32%) |
23 (37%) |
9 (25%) |
0.27 |
| Diabetes Mellitus |
23 (23%) |
13 (21%) |
10 (28%) |
0.50 |
| COPD |
7 (7%) |
4 (6%) |
3 (8%) |
0.70 |
| Chronic kidney disease (MDRD <30) |
4 (4%) |
2 (3%) |
2 (6%) |
0.62 |
| ECG characteristics |
| LBBB |
72 (73%) |
54 (86%) |
18 (50%) |
<0.001 |
| QRSD [ms] |
166 ± 22 |
167 ± 16 |
163 ± 29 |
0.37 |
| QRSD >150 ms |
78 (79%) |
54 (86%) |
24 (67%) |
0.04 |
| Laboratory parameters |
| MDRD [mL/min/1.73 m2] |
58 (45–61) |
60 (50–61) |
53 (43–60) |
0.07 |
| NT-proBNP (pg/mL) |
1438 (626–2791) |
1226 (567–2009) |
1776 (1184–3298) |
0.04 |
| Echocardiographic parameters |
| LVEDV (mL/m2) |
117 (107–138) |
115 (100–136) |
122 (109–142) |
0.06 |
| LVESV (mL/m2) |
87 (71–106) |
84 (70–103) |
89 (75–108) |
0.25 |
| LVEF (%) |
28 ± 8 |
28 ± 7 |
27 ± 8 |
0.32 |
| LAVI (mL/m2) |
40 (31–52) |
36 (28–47) |
45 (37–60) |
<0.001 |
| LASr (%) |
16 (10–21) |
18 (12–22) |
12 (8–17) |
<0.005 |
| Mitral regurgitation ≥ moderate (n, %) |
34 (34%) |
18 (29%) |
16 (44%) |
0.13 |
| NYHA functional class |
| II / III / IV |
35/62/2 (35%/63%/2%) |
25/37/1 (40%/59%/2%) |
10/25/1 (28%/69%/3%) |
0.37 |
| Heart failure medication |
| Beta-blocker |
85 (86%) |
55 (87%) |
30 (83%) |
0.77 |
| Renin-angiotensin system antagonist |
89 (90%) |
58 (92%) |
31 (86%) |
0.49 |
| Mineralocorticoid antagonist |
36 (36%) |
20 (32%) |
16 (44%) |
0.28 |
| Lis diuretics |
59 (60%) |
32 (51%) |
27 (75%) |
0.02 |
, 
